• Prophylactic Radical Fimbriectomy with Delayed Oophorectomy in Women with a High Risk of Developing an Ovarian Carcinoma: Results of a Prospective National Pilot Study.
    • Leblanc E, Narducci F, Ferron G, Mailliez A, Charvolin JY, El Hajj H, Guyon F, Fourchotte V, Lambaudie E, Crouzet A, Fouche Y, Gouy S, Collinet P, Caquant F, Pomel C, Golfier F, Vaini-Cowen V, Fournier I, Salzet M, Tresch E, Probst A, Lemaire AS, Le Deley MC, Hudry D.
    • Cancers (Basel). 2023 Feb 10;15(4):1141. doi: 10.3390/cancers15041141.

    •• Identifier: NCT01608074: Radical Fimbriectomy for Young BRCA Mutation Carriers (Fimbriectomy). (ClinicalTrials.gov . Accessed 2023 Feb 12.)

    • Uptake and Effectiveness of Risk-Reducing Surgeries in Unaffected Female BRCA1 and BRCA2 Carriers: A Single Institution Experience in the Czech Republic.
    • Zimovjanova M, Bielcikova Z, Miskovicova M, Vocka M, Zimovjanova A, Marian Rybar M, Novotny J, Petruzelka L.
    • Cancers (Basel). 2023 Feb 8;15(4):1072. doi: 10.3390/cancers15041072.
    • Long-Term Non-Cancer Risks in People with BRCA Mutations following Risk-Reducing Bilateral Salpingo-Oophorectomy and the Role of Hormone Replacement Therapy: A Review.
    • Nitschke AS, Abreu do Valle H, Dawson L, Kwon JS, Hanley GE.
    • Cancers (Basel). 2023 Jan 24;15(3):711. doi: 10.3390/cancers15030711.
    • The Role of Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows.
    • Loizzi V, Dellino M, Cerbone M, Arezzo F, Cazzato G, Damiani GR, Pinto V, Silvestris E, Kardhashi A, Cicinelli E, Cascardi E, Cormio G.
    • Int J Mol Sci. 2023 Jan 1;24(1):764. doi: 10.3390/ijms24010764.
    • The risks of cancer in older women with BRCA pathogenic variants: How far have we come?
    • Metcalfe KA, Gronwald J, Tung NM, McCuaig JM, Eisen A, Elser C, Foulkes WD, Neuhausen SL, Senter L, Moller P, Bordeleau L, Fruscio R, Velsher L, Zakalik D, Olopade OI, Eng C, Pal T, Cullinane CA, Couch FJ, Kotsopoulos J, Sun P, Lubinski J, Narod SA.
    • Cancer. 2022 Dec 26. doi: 10.1002/cncr.34615. Epub ahead of print.
    • Pathologic Findings at Risk Reducing Surgery in BRCA and Non-BRCA Mutation Carriers: A Single-Center Experience.
    • Cassani C, Rossi C, Camnasio CA, Urtis M, Fiandrino G, Grasso M, Zanellini F, Lucioni M, D’Ambrosio G, Di Toro A, Rossi M, Roccio M, Ferrari A, Secondino S, Nappi RE, Arbustini E, Paulli M, Spinillo A, Cesari S.
    • Diagnostics (Basel). 2022 Dec 6;12(12):3054. doi: 10.3390/diagnostics12123054.
    • Considerations for the Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy.
    • Zhang J, Liu M.
    • J Clin Oncol. 2022 Nov 10;40(32):3783. doi: 10.1200/JCO.22.00726. Epub 2022 Jul 12.

    •• Original research:

    Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis.

    •• Reply, Letter:

    Reply to J. Zhang et al.

    • The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2.
    • Philpott S, Raikou M, Manchanda R, Lockley M, Singh N, Scott M, Evans DG, Adlard J, Ahmed M, Edmondson R, Woodward ER, Lamnisos A, Balega J, Brady AF, Sharma A, Izatt L, Kulkarni A, Tripathi V, Solomons JS, Hayes K, Hanson H, Snape K, Side L, Skates S, McGuire A, Rosenthal AN.
    • J Med Genet. 2022 Nov 1:jmedgenet-2022-108741. doi: 10.1136/jmg-2022-108741. Epub ahead of print.
    • Outcome and management of STIC following opportunistic salpingectomy: systematic review and meta-analysis.
    • Ruel-Laliberté J, Kasasni SM, Oprea D, Viau M.
    • J Obstet Gynaecol Can. 2022 Sep 10:S1701-2163(22)00612-0. doi: 10.1016/j.jogc.2022.08.018. Epub ahead of print.
    • Meta-Analysis
    • Peritoneal dissemination of high-grade serous ovarian cancer: pivotal roles of chromosomal instability and epigenetic dynamics.
    • Konishi I, Abiko K, Hayashi T, Yamanoi K, Murakami R, Yamaguchi K, Hamanishi J, Baba T, Matsumura N, Mandai M; Kyoto Study Group for Ovarian Cancer Research.
    • J Gynecol Oncol. 2022 Sep;33(5):e83. doi: 10.3802/jgo.2022.33.e83.
    • A prospective multicentric study of risk-reducing salpingo-oophorectomy in BRCA mutation patients.
    • Loizzi V, Cicinelli E, Del Vecchio V, Arezzo F, Deromemaj X, Kardhashi A, Paradiso A, Legge F, Natalicchio MI, Resta L, Resta N, Loconte DC, Cormio G.
    • Acta Biomed. 2022 Aug 31;93(4):e2022051. doi: 10.23750/abm.v93i4.11695.
    • Incidence of pelvic high-grade serous carcinoma after isolated STIC diagnosis: A systematic review of the literature.
    • Linz VC, Löwe A, van der Ven J, Hasenburg A, Battista MJ.
    • Front Oncol. 2022 Aug 31;12:951292. doi: 10.3389/fonc.2022.951292.
    • Surgical management of BRCA-mutation carriers: A single institution experience.
    • Gentile D, Losurdo A, Sagona A, Zuradelli M, Gatzemeier W, Barbieri E, Testori A, Errico V, Bianchi P, Biondi E, Torrisi R, Santoro A, Tinterri C.
    • Eur J Surg Oncol. 2022 Aug;48(8):1706-1712. doi: 10.1016/j.ejso.2022.04.024. Epub 2022 Apr 30.
    • Study: Risk-reducing ovarian cancer surgery and quality of life.
    • [No author given]
    • FORCE. XRAY. 2022 Jul 26.

    Original research:

    Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.

    • Risk reducing surgery with peritoneal staging in BRCA1-2 mutation carriers. A prospective study.
    • Marchetti C, Arcieri M, Vertechy L, Ergasti R, Russo G, Zannoni GF, Minucci A, Ercoli A, Scambia G, Fagotti A.
    • Eur J Surg Oncol. 2022 Jul 19:S0748-7983(22)00549-2. doi: 10.1016/j.ejso.2022.07.007. Epub ahead of print.
    • Differences in age at diagnosis of ovarian cancer for each BRCA mutation type in Japan: optimal timing to carry out risk-reducing salpingo-oophorectomy.
    • Sekine M, Enomoto T, Arai M, Den H, Nomura H, Ikeuchi T, Nakamura S; Registration Committee of the Japanese Organization of Hereditary Breast and Ovarian Cancer.
    • J Gynecol Oncol. 2022 Jul;33(4):e46. doi: 10.3802/jgo.2022.33.e46. Epub 2022 Mar 31.
    • TP53 variants in p53 signatures and the clonality of STICs in RRSO samples.
    • Akahane T, Masuda K, Hirasawa A, Kobayashi Y, Ueki A, Kawaida M, Misu K, Nakamura K, Nagai S, Chiyoda T, Yamagami W, Hayashi S, Kataoka F, Banno K, Sugano K, Okita H, Kosaki K, Nishihara H, Aoki D.
    • J Gynecol Oncol. 2022 Jul;33(4):e50. doi: 10.3802/jgo.2022.33.e50. Epub 2022 Mar 21.
    • Genomic catastrophe, the peritoneal cavity and ovarian cancer prevention.
    • Yoon JY, Chapel DB, Goebel E, Qian X, Mito JK, Horowitz NS, Miron A, Soong TR, Xian W, Crum CP.
    • J Pathol. 2022 Jul;257(3):255-261. doi: 10.1002/path.5891. Epub 2022 Apr 18.
    • Review
    • Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis.
    • Steenbeek MP, van Bommel MHD, Bulten J, Hulsmann JA, Bogaerts J, Garcia C, Cun HT, Lu KH, van Beekhuizen HJ, Minig L, Gaarenstroom KN, Nobbenhuis M, Krajc M, Rudaitis V, Norquist BM, Swisher EM, Mourits MJE, Massuger LFAG, Hoogerbrugge N, Hermens RPMG, IntHout J, de Hullu JA.
    • J Clin Oncol. 2022 Jun 10;40(17):1879-1891. doi: 10.1200/JCO.21.02016. Epub 2022 Mar 18.
    • Meta-Analysis

    •• Commentary:

    Risk of Peritoneal Cancer After Risk-Reducing Bilateral Salpingo-Oophorectomy for Women With Germline BRCA Pathogenic Variants: A Cause for Concern or Potentially Avoidable?

    •• Letter, Commentary:

    Considerations for the Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy.

    •• Reply, Letter:

    Reply to J. Zhang et al.

    • Prophylactic Salpingo-Opphorectomy in Patients With Hereditary Predisposition Genes for Ovarian Cancer.
    • Garrett AA, Mahdi H.
    • JCO Oncol Pract. 2022 Jun;18(6):e846-e848. doi: 10.1200/OP.22.00069. Epub 2022 Mar 8.

    Original research:

    Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes.

    • Familial risk of epithelial ovarian cancer after accounting for gynaecological surgery: a population-based study.
    • Barnard ME, Meeks H, Jarboe EA, Albro J, Camp NJ, Doherty JA.
    • J Med Genet. 2022 May 9:jmedgenet-2021-108402. doi: 10.1136/jmedgenet-2021-108402. Epub ahead of print.
    • Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.
    • Schrijver LH, Mooij TM, Pijpe A, Sonke GS, Mourits MJE, Andrieu N, Antoniou AC, Easton DF, Engel C, Goldgar D, John EM, Kast K, Milne RL, Olsson H, Phillips KA, Terry MB, Hopper JL, van Leeuwen FE, Rookus MA.
    • J Natl Cancer Inst. 2022 Apr 11;114(4):540-552. doi: 10.1093/jnci/djac004.


    Oral Contraceptives and BRCA Cancer: A Balancing Act.

    • Fallopian Tube Originating Ovarian Cancer in a 53-Year-Old Postmenopausal Female With Hereditary Breast Cancer (BRCA) Genes: A Case Study.
    • Garrick I, Ahasan H, Jiang M, Musheyev Y, Ftiha F, Levada M.
    • Cureus. 2022 Apr 7;14(4):e23929. doi: 10.7759/cureus.23929.
    • Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer.
    • Rhiem K, Auber B, Briest S, Dikow N, Ditsch N, Dragicevic N, Grill S, Hahnen E, Horvath J, Jaeger B, Kast K, Kiechle M, Leinert E, Morlot S, Püsken M, Schäfer D, Schott S, Schroeder C, Siebers-Renelt U, Solbach C, Weber-Lassalle N, Witzel I, Zeder-Göß C, Schmutzler RK.
    • Breast Care (Basel). 2022 Apr;17(2):199-207. doi: 10.1159/000516376. Epub 2021 Jul 19.
    • Recommendations for diagnosing STIC: a systematic review and meta-analysis.
    • Bogaerts JMA, Steenbeek MP, van Bommel MHD, Bulten J, van der Laak JAWM, de Hullu JA, Simons M.
    • Virchows Arch. 2022 Apr;480(4):725-737. doi: 10.1007/s00428-021-03244-w. Epub 2021 Dec 1.
    • Risk-Reducing Options for High-Grade Serous Gynecologic Malignancy in BRCA1/2.
    • Clarfield L, Diamond L, Jacobson M.
    • Curr Oncol. 2022 Mar 21;29(3):2132-2140. doi: 10.3390/curroncol29030172.
    • Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes.
    • Liu YL, Breen K, Catchings A, Ranganathan M, Latham A, Goldfrank DJ, Grisham RN, Long Roche K, Frey MK, Chi DS, Abu-Rustum N, Aghajanian C, Offit K, Stadler ZK.
    • JCO Oncol Pract. 2022 Mar;18(3):201-209. doi: 10.1200/OP.21.00382. Epub 2021 Sep 28.


    Prophylactic Salpingo-Opphorectomy in Patients With Hereditary Predisposition Genes for Ovarian Cancer.

    • Earlier decisions on breast and ovarian surgery reduce cancer in women at high risk.
    • Saul H, Gursul D, Cassidy S, Evans G.
    • BMJ. 2022 Feb 15;376:o258. doi: 10.1136/bmj.o258.
    • Research news

    Original research:

    Uptake and efficacy of bilateral risk reducing surgery in unaffected female BRCA1 and BRCA2 carriers.

    • Serous Tubal Intraepithelial Carcinoma in a Risk-reducing Salpingo-oophorectomy Specimen From a RAD51D Mutation Carrier: A Case Report.
    • Gregory-Davis KJ, Walker A, Colello LS, McKinnon W, Everett E, Chang MC.
    • Int J Gynecol Pathol. 2022 Feb 11. doi: 10.1097/PGP.0000000000000857. Epub ahead of print.
    • Case report
    • Chris Evert's ovarian cancer diagnosis highlights the importance of genetic counseling and testing.
    • [No author given]
    • FORCE. XRAY. 2022 Feb 8.

    Press: Chris Evert opens up about her stage 1C ovarian cancer diagnosis. (ESPN)

    • Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond BRCA1 and BRCA2.
    • Samuel D, Diaz-Barbe A, Pinto A, Schlumbrecht M, George S.
    • Cells. 2022 Feb 4;11(3):539. doi: 10.3390/cells11030539.
    • Uptake and efficacy of bilateral risk reducing surgery in unaffected female BRCA1 and BRCA2 carriers.
    • Marcinkute R, Woodward ER, Gandhi A, Howell S, Crosbie EJ, Wissely J, Harvey J, Highton L, Murphy J, Holland C, Edmondson R, Clayton R, Barr L, Harkness EF, Howell A, Lalloo F, Evans DG.
    • J Med Genet. 2022 Feb;59(2):133-140. doi: 10.1136/jmedgenet-2020-107356. Epub 2021 Feb 10.

    Research news:

    Earlier decisions on breast and ovarian surgery reduce cancer in women at high risk.

    • Long-term tumour dormancy in a BRCA1 heterozygote.
    • Amuzu S, Fu L, Demko N, Rivera B, Domecq C, de Kock L, Hamel N, Gilbert L, Polak P, Ragoussis J, Foulkes WD.
    • J Med Genet. 2022 Jan 17:jmedgenet-2021-108269. doi: 10.1136/jmedgenet-2021-108269. Epub ahead of print.
    • Case report
    • Tubal histopathological abnormalities in BRCA1/2 mutation carriers undergoing prophylactic salpingo-oophorectomy: a case-control study.
    • Sina F, Cassani C, Comerio C, De Ponti E, Zanellini F, Delle Marchette M, Roversi G, Jaconi M, Arbustini E, Urtis M, Dell'Oro C, Zambetti B, Paniga C, Acampora E, Negri S, Lazzarin S, Cesari S, Spinillo A, Kotsopoulos J, Fruscio R.
    • Int J Gynecol Cancer. 2022 Jan;32(1):41-47. doi: 10.1136/ijgc-2021-003153. Epub 2021 Nov 29.
    • Evidence for Diverse Prognosis in High-Grade Serous Ovarian Carcinoma: Solid, Pseudoendometrioid, and Transitional-Like; So-Called "SET Morphology" and Progesterone Receptor Status.
    • Uner H, Demir M, Goksuluk D, Kars A, Uner M, Usubutun A.
    • Turk Patoloji Derg. 2022;38(3):240-250. English. doi: 10.5146/tjpath.2022.01571.
    • Metastatic ovarian carcinoma in breast cancer patients during risk-reducing salpingo-oophorectomy: Report of two cases.
    • Shakya P, Bajracharya A, Shrestha S, Kharel S, Maharjan R, Shrestha AK.
    • Ann Med Surg (Lond). 2021 Dec 6;73:103158. doi: 10.1016/j.amsu.2021.103158. eCollection 2022 Jan.
    • Uptake Rate of Risk-Reducing Salpingo-Oophorectomy and Surgical Outcomes of Female Germline BRCA1/2 Mutation Carriers: A Retrospective Cohort Study.
    • Lim H, Kim SI, Hyun S, Lee GB, Seol A, Lee M.
    • Yonsei Med J. 2021 Dec;62(12):1090-1097. doi: 10.3349/ymj.2021.62.12.1090.
    • Association of Premenopausal Bilateral Oophorectomy With Cognitive Performance and Risk of Mild Cognitive Impairment.
    • Rocca WA, Lohse CM, Smith CY, Fields JA, Machulda MM, Mielke MM.
    • JAMA Netw Open. 2021 Nov 1;4(11):e2131448. doi: 10.1001/jamanetworkopen.2021.31448.


    Long-term Risk of Cognitive Impairment and Dementia Following Bilateral Oophorectomy in Premenopausal Women-Time to Rethink Policies?

    • Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC).
    • Saccardi C, Zovato S, Spagnol G, Bonaldo G, Marchetti M, Alessandrini L, Tognazzo S, Guerriero A, Vitagliano A, Laganà AS, Noventa M.
    • Gynecol Oncol. 2021 Nov;163(2):364-370. doi: 10.1016/j.ygyno.2021.08.021. Epub 2021 Aug 28.
    • What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 12 months after premenopausal risk-reducing salpingo-oophorectomy.
    • Hickey M, Moss KM, Krejany EO, Wrede CD, Brand A, Kirk J, Symecko HL, Domchek SM, Tejada-Berges T, Trainer A, Mishra GD.
    • Gynecol Oncol. 2021 Oct;163(1):148-154. doi: 10.1016/j.ygyno.2021.07.029. Epub 2021 Jul 24.
    • Role of Routine Peritoneal Biopsies During Risk Reducing Salpingo-Oophorectomy (RRSO).
    • Pross T, Karsten MM, Blohmer JU, Speiser D.
    • Geburtshilfe Frauenheilkd. 2021 Sep;81(9):1031-1038. doi: 10.1055/a-1395-7715. Epub 2021 Sep 13.
    • Risk of cardiovascular disease among women carrying BRCA mutations after risk-reducing bilateral salpingo-oophorectomy: A population-based study.
    • do Valle HA, Kaur P, Kwon JS, Cheifetz R, Dawson L, Hanley GE.
    • Gynecol Oncol. 2021 Sep;162(3):707-714. doi: 10.1016/j.ygyno.2021.06.022. Epub 2021 Jul 1.
    • Surgical Management of Hereditary Breast Cancer.
    • Berger ER, Golshan M.
    • Genes (Basel). 2021 Aug 31;12(9):1371. doi: 10.3390/genes12091371.
    • Clinical and pathological outcomes of risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer.
    • Nomura H, Ikki A, Fusegi A, Omi M, Aoki Y, Netsu S, Tanigawa T, Matoda M, Okamoto S, Omatsu K, Nakajima T, Ueki A, Tonooka A, Kanao H.
    • Int J Clin Oncol. 2021 Aug 28. doi: 10.1007/s10147-021-02020-9. Epub ahead of print.
    • The impact of risk reducing bilateral salpingo-oophorectomy on sexual function in BRCA1/2 mutation carriers and women with Lynch syndrome: A systematic review and meta-analysis.
    • Kershaw V, Hickey I, Wyld L, Jha S.
    • Eur J Obstet Gynecol Reprod Biol. 2021 Aug 8;265:7-17. doi: 10.1016/j.ejogrb.2021.08.001. Epub ahead of print.
    • Review
    • Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.
    • Steenbeek MP, Harmsen MG, Hoogerbrugge N, de Jong MA, Maas AHEM, Prins JB, Bulten J, Teerenstra S, van Bommel MHD, van Doorn HC, Mourits MJE, van Beurden M, Zweemer RP, Gaarenstroom KN, Slangen BFM, Brood-van Zanten MMA, Vos MC, Piek JMJ, van Lonkhuijzen LRCW, Apperloo MJA, Coppus SFPJ, Massuger LFAG, IntHout J, Hermens RPMG, de Hullu JA.
    • JAMA Oncol. 2021 Aug 1;7(8):1203-1212. doi: 10.1001/jamaoncol.2021.1590.

    Identifier: NCT02321228: Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers (TUBA). (ClinicalTrials.gov)

    Research news: Study: Risk-reducing ovarian cancer surgery and quality of life. (FORCE. XRAY.)

    • What happens after menopause? (WHAM): A prospective controlled study of sleep quality up to 12 months after premenopausal risk-reducing salpingo-oophorectomy.
    • Hickey M, Moss KM, Krejany EO, Wrede CD, Domchek SM, Kirk J, Brand A, Trainer A, Mishra GD, Baker FC.
    • Gynecol Oncol. 2021 Aug;162(2):447-453. doi: 10.1016/j.ygyno.2021.05.036. Epub 2021 Jun 8.
    • Follow-up of tissue genomics in BRCA1/2 carriers who underwent prophylactic surgeries.
    • Kotoula V, Papadopoulou K, Tikas I, Fostira F, Vrettou E, Chrisafi S, Fountzilas E, Koliou GA, Apostolou P, Papazisis K, Zaramboukas T, Asimaki-Vlachopoulou A, Miliaras S, Ananiadis A, Poulios C, Natsiopoulos I, Tsiftsoglou A, Demiri E, Fountzilas G.
    • Breast Cancer. 2021 Jul 24. doi: 10.1007/s12282-021-01276-3. Epub ahead of print.
    • Risk of epithelial ovarian cancer Type I and II after hysterectomy, salpingectomy and tubal ligation - A nationwide case control study.
    • Darelius A, Kristjansdottir B, Dahm-Kähler P, Strandell A.
    • Int J Cancer. 2021 Jun 21. doi: 10.1002/ijc.33714. Epub ahead of print.
    • An evaluation of memory and attention in BRCA mutation carriers using an online cognitive assessment tool.
    • Kotsopoulos J, Kim SJ, Armel S, Bordeleau L, Foulkes WD, McKinnon W, Panchal S, Cohen SA, Sun S, Sun P, McKetton L, Troyer AK, Narod SA.
    • Cancer. 2021 Jun 2. doi: 10.1002/cncr.33654. Epub ahead of print.
    • Gynecological lesions in hereditary cancer predisposition syndromes.
    • Dundr P, Cibula D, Foretová L, Macek M Jr, Kopecková K, Petruželka L, Nemejcová K, Bártu M, Hojný J, Hájková N, Jakša R, Janega P, Stružinská I.
    • Cesk Patol. 2021 Summer;57(2):96-104. English.
    • BRCA Genetic Test and Risk-Reducing Salpingo-Oophorectomy for Hereditary Breast and Ovarian Cancer: State-of-the-Art.
    • Sekine M, Nishino K, Enomoto T.
    • Cancers (Basel). 2021 May 23;13(11):2562. doi: 10.3390/cancers13112562.
    • Plasma Protein Biomarkers Associated with Higher Ovarian Cancer Risk in BRCA1/2 Carriers.
    • Ahn HS, Ho JY, Yu J, Yeom J, Lee S, Hur SY, Jung Y, Kim K, Choi YJ.
    • Cancers (Basel). 2021 May 11;13(10):2300. doi: 10.3390/cancers13102300.
    • A rectovaginal septum mass in a BRCA1 positive patient years after risk reducing surgery: A case report.
    • Blankenship L, Lyons YA, Dao Campi H, Valente PT, Barnes L, Kost ER.
    • Gynecol Oncol Rep. 2021 May 5;36:100772. doi: 10.1016/j.gore.2021.100772.
    • Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review.
    • Huber D, Seitz S, Kast K, Emons G, Ortmann O.
    • J Cancer Res Clin Oncol. 2021 Apr 22. doi: 10.1007/s00432-021-03629-z. Epub ahead of print.
    • Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report.
    • Dominguez-Valentin M, Crosbie EJ, Engel C, Aretz S, Macrae F, Winship I, Capella G, Thomas H, Nakken S, Hovig E, Nielsen M, Sijmons RH, Bertario L, Bonanni B, Tibiletti MG, Cavestro GM, Mints M, Gluck N, Katz L, Heinimann K, Vaccaro CA, Green K, Lalloo F, Hill J, Schmiegel W, Vangala D, Perne C, Strauß HG, Tecklenburg J, Holinski-Feder E, Steinke-Lange V, Mecklin JP, Plazzer JP, Pineda M, Navarro M, Vidal JB, Kariv R, Rosner G, Piñero TA, Gonzalez ML, Kalfayan P, Ryan N, Ten Broeke SW, Jenkins MA, Sunde L, Bernstein I, Burn J, Greenblatt M, de Vos Tot Nederveen Cappel WH, Della Valle A, Lopez-Koestner F, Alvarez K, Büttner R, Görgens H, Morak M, Holzapfel S, Hüneburg R, von Knebel Doeberitz M, Loeffler M, Rahner N, Weitz J, Pylvänäinen K, Renkonen-Sinisalo L, Lepistö A, Auranen A, Hopper JL, Win AK, Haile RW, Lindor NM, Gallinger S, Le Marchand L, Newcomb PA, Figueiredo JC, Thibodeau SN, Therkildsen C, Okkels H, Ketabi Z, Denton OG, Rødland EA, Vasen H, Neffa F, Esperon P, Tjandra D, Möslein G, Sampson JR, Evans DG, Seppälä TT, Møller P.
    • Genet Med. 2021 Apr;23(4):705-712. doi: 10.1038/s41436-020-01029-1. Epub 2020 Dec 1.
    • Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers.
    • Cowan R, Nobre SP, Pradhan N, Yasukawa M, Zhou QC, Iasonos A, Soslow RA, Arnold AG, Trottier M, Catchings A, Roche KL, Gardner G, Robson M, Abu Rustum NR, Aghajanian C, Cadoo K.
    • Gynecol Oncol. 2021 Mar 9:S0090-8258(21)00142-6. doi: 10.1016/j.ygyno.2021.02.006. Epub ahead of print.
    • Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels.
    • Crosbie EJ, Flaum N, Harkness EF, Clayton RD, Holland C, Martin-Hirsch P, Wood N, Keating P, Woodward ER, Lalloo F, Donnai P, Edmondson RJ, Evans DG.
    • Int J Cancer. 2021 Mar 1;148(5):1155-1163. doi: 10.1002/ijc.33378. Epub 2020 Nov 11.
    • Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy?
    • Grandi G, Perrone AM, Perrone A, Mandato VD, Comerci G, Sammarini M, Merisio C, Amadori A, Stefanetti M, Martinello R, Facchinetti F, De Iaco P; Brca Emilia-Romagna Gyneco-Oncological (BERGO) Collaborative Group.
    • Maturitas. 2021 Jan;143:59-64. doi: 10.1016/j.maturitas.2020.08.011. Epub 2020 Aug 31.
    • Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report.
    • Kuji S, Kondo H, Ohara T, Deura I, Tozawa-Ono A, Migita O, Kawamoto H, Tsugawa K, Chosokabe M, Koike J, Maeda I, Suzuki N.
    • Jpn J Clin Oncol. 2020 Dec 30:hyaa239. doi: 10.1093/jjco/hyaa239. Epub ahead of print.
    • Association between BRCA mutations and endometrial carcinoma: a systematic review with meta-analysis.
    • Lu G, Lu T, Pan J, Guo L, Pang Y, Liu P.
    • Arch Gynecol Obstet. 2020 Nov 20. doi: 10.1007/s00404-020-05887-7.
    • Review
    • No signs of subclinical atherosclerosis after risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers.
    • van Bommel MHD, de Jong MA, Steenbeek MP, Bots ML, van Westerop LLM, Hopman MTE, Hoogerbrugge N, de Hullu JA, Maas AHEM.
    • J Cardiol. 2020 Nov 20:S0914-5087(20)30364-6. doi: 10.1016/j.jjcc.2020.11.005. Epub ahead of print.
    • Assessing Effectiveness of Colonic and Gynecological Risk Reducing Surgery in Lynch Syndrome Individuals.
    • Dueñas N, Navarro M, Teulé À, Solanes A, Salinas M, Iglesias S, Munté E, Ponce J, Guardiola J, Kreisler E, Carballas E, Cuadrado M, Matias-Guiu X, de la Ossa N, Lop J, Lázaro C, Capellá G, Pineda M, Brunet J.
    • Cancers (Basel). 2020 Nov 18;12(11):3419. doi: 10.3390/cancers12113419.
    • Radiologic-Histopathologic Correlation of Transvaginal US and Risk-reducing Salpingo-oophorectomy for Women at High Risk for Tubo-ovarian Carcinoma.
    • Sakala MD, Curci NE, Masch WR, Mendiratta-Lala M, Stein EB, Wasnik AP, Sciallis AP, Uppal S, Pearlman MD, Maturen KE.
    • Radiol Imaging Cancer. 2020 Nov 13;2(6):e190086. doi: 10.1148/rycan.2020190086.
    • Retrospective evaluation of risk-reducing salpingo-oophorectomy for BRCA1/2 pathogenic variant carriers among a cohort study in a single institution.
    • Kobayashi Y, Hirasawa A, Chiyoda T, Ueki A, Masuda K, Misu K, Kawaida M, Hayashi S, Kataoka F, Banno K, Kosaki K, Aoki D.
    • Jpn J Clin Oncol. 2020 Oct 10:hyaa173. doi: 10.1093/jjco/hyaa173. Epub ahead of print.
    • Short- and long-term outcomes for single-port risk-reducing salpingo-oophorectomy with and without hysterectomy for women at risk for gynecologic cancer.
    • Carr CE, Chambers L, Jernigan AM, Freeman L, Escobar PF, Michener CM.
    • Int J Gynecol Cancer. 2020 Sep 18:ijgc-2020-001405. doi: 10.1136/ijgc-2020-001405. Epub ahead of print.
    • Cardiovascular Prevention in Individuals at High Risk of Developing Cancer.
    • Oren O, Kopecky SL, Blumenthal RS, Gersh BJ, Yang EH.
    • JACC CardioOncol. 2020 Sep 15;2(3):527-531. doi: 10.1016/j.jaccao.2020.07.002.
    • Cytologic studies of in vivo fallopian tube specimens in patients undergoing salpingo-oophorectomy.
    • Pramanik S, Yang E, Wu W.
    • Cytojournal. 2020 Aug 10;17:19. doi: 10.25259/CytoJournal_7_2020.
    • Penetrance of Breast and Ovarian Cancer in Women Who Carry a BRCA1/2 Mutation and Do Not Use Risk-Reducing Salpingo-Oophorectomy: An Updated Meta-Analysis.
    • Chen J, Bae E, Zhang L, Hughes K, Parmigiani G, Braun D, Rebbeck TR.
    • JNCI Cancer Spectr. 2020 Apr 23 [eCollection 2020 Aug.];4(4):pkaa029. doi: 10.1093/jncics/pkaa029.
    • Ovarian Cancer After Prophylactic Salpingectomy in a Patient With Germline BRCA1 Mutation.
    • Lugo Santiago N, Smith E, Cox M, Wan CS, Tchabo NE, Awowole I, Broach V, Chi DS.
    • Obstet Gynecol. 2020 Jun;135(6):1270-1274. doi: 10.1097/AOG.0000000000003864.
    • Case report


    Too Good to Be True.

    • The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study.
    • Gornjec A, Merlo S, Novakovic S, Stegel V, Gazic B, Perhavec A, Blatnik A, Krajc M.
    • Radiol Oncol. 2020 May 28;54(2):180-186. doi: 10.2478/raon-2020-0020.
    • Long-term outcomes following a diagnosis of ovarian cancer at the time of preventive oophorectomy among BRCA1 and BRCA2 mutation carriers.
    • Kotsopoulos J, Karlan B, Gronwald J, Hall E, Moller P, Tung N, Zakalik D, Foulkes WD, Rosen B, Neuhausen SL, Sun P, Lubinksi J, Narod SA.
    • Int J Gynecol Cancer. 2020 Apr 30. pii: ijgc-2019-001141. doi: 10.1136/ijgc-2019-001141. [Epub ahead of print]
    • Primary fallopian tube carcinoma (PFTC) in a BRIP-1 mutation carrier: the first case report.
    • Grandi G, Caroli M, Alboni C, Cortesi L, Toss A, Barbieri E, Botticelli L, Facchinetti F.
    • Fam Cancer. 2020 Apr 24. doi: 10.1007/s10689-020-00179-0. [Epub ahead of print]
    • Case report
    • Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
    • Rush SK, Swisher EM, Garcia RL, Pennington KP, Agnew KJ, Kilgore MR, Norquist BM.
    • Gynecol Oncol. 2020 Mar 18. pii: S0090-8258(20)30101-3. doi: 10.1016/j.ygyno.2020.02.006. [Epub ahead of print]
    • Is hormonal therapy after risk-reducing salpingo-oophorectomy associated with an increased risk of malignancy in pathogenic variant carriers?
    • Mills KA, Joshi TV, West L, Kuznicki M, Kent L, Hokenstad AN, Cripe JC, Woolfolk C, Senter L, Bakkum-Gamez JN, Wenham RM, Cohn DE, Bae-Jump V, Thaker PH.
    • Gynecol Oncol. 2020 Mar 3. pii: S0090-8258(20)30179-7. doi: 10.1016/j.ygyno.2020.02.033. [Epub ahead of print]
    • Occult Tubal Carcinoma After Risk-Reducing Salpingo-oophorectomy: A Systematic Review.
    • Piedimonte S, Frank C, Laprise C, Quaiattini A, Gotlieb WH.
    • Obstet Gynecol. 2020 Mar;135(3):498-508. doi: 10.1097/AOG.0000000000003702.
    • Review


    Unanswered Questions in High-Risk Women Undergoing Risk-Reducing Salpingo-oophorectomy.

    Press: Cancer Threat Persists After Risk-Reducing Surgery — Occult tumors, recurrence, new cancers after prophylactic salpingo-oophorectomy. (Medpage Today)

    • Serous Tubal Intraepithelial Carcinoma: A Concise Review for the Practicing Pathologist and Clinician.
    • Bachert SE, McDowell A Jr, Piecoro D, Baldwin Branch L.
    • Diagnostics (Basel). 2020 Feb 13;10(2). pii: E102. doi: 10.3390/diagnostics10020102.
    • Incidental Serous Tubal Intraepithelial Carcinoma that Developed into Primary Peritoneal Serous Carcinoma in a Patient without BRCA Mutation.
    • Chong GO, Park JY, Lee HJ.
    • Am J Case Rep. 2020 Feb 8;21:e921146. doi: 10.12659/AJCR.921146.
    • The incidence of occult ovarian neoplasia and cancer in BRCA1/2 mutation carriers after the bilateral prophylactic salpingo-oophorectomy (PBSO): A single-center prospective study.
    • Rudaitis V, Mikliusas V, Januska G, Jukna P, Mickys U, Janavicius R.
    • Eur J Obstet Gynecol Reprod Biol. 2020 Jan 30;247:26-31. doi: 10.1016/j.ejogrb.2020.01.040. [Epub ahead of print]
    • Risk-Reducing Bilateral Salpingo-Oophorectomy: Assessing the Incidence of Occult Ovarian Cancer and Surgeon Adherence to Recommended Practices.
    • Newcomb LK, Toal CT, Rindos NB, Wang L, Mansuria SM.
    • J Minim Invasive Gynecol. 2020 Jan 9. pii: S1553-4650(20)30037-6. doi: 10.1016/j.jmig.2020.01.004. [Epub ahead of print]
    • Increased Overall Mortality Even after Risk Reducing Surgery for BRCA-Positive Women in Western Sweden.
    • Öfverholm A, Einbeigi Z, Wigermo A, Holmberg E, Karsson P.
    • Genes (Basel). 2019 Dec 16;10(12). pii: E1046. doi: 10.3390/genes10121046.
    • Peritoneal cancer after bilateral mastectomy, hysterectomy, and bilateral salpingo-oophorectomy with a poor prognosis: A case report and review of the literature.
    • Ma YN, Bu HL, Jin CJ, Wang X, Zhang YZ, Zhang H.
    • World J Clin Cases. 2019 Nov 26;7(22):3872-3880. doi: 10.12998/wjcc.v7.i22.3872.
    • A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy.
    • Gronwald J, Lubinski J, Huzarski T, Cybulski C, Menkiszak J, Siołek M, Stawicka M, Sun P, Kim S, Kotsopoulos J, Narod SA.
    • Gynecol Oncol. 2019 Sep 6. pii: S0090-8258(19)31486-6. doi: 10.1016/j.ygyno.2019.08.034. [Epub ahead of print]
    • Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: A systematic review and meta-analysis.
    • Cheng A, Li L, Wu M, Lang J.
    • Eur J Surg Oncol. 2019 Sep 5. pii: S0748-7983(19)30662-6. doi: 10.1016/j.ejso.2019.09.002. [Epub ahead of print]
    • A Microsimulation Model for Evaluating the Effectiveness of Cancer Risk Management for BRCA Pathogenic Variant Carriers: miBRovaCAre.
    • Petelin L, Hossack L, Mitchell G, Liew D, Trainer AH, James PA.
    • Value Health. 2019 Aug;22(8):854-862. doi: 10.1016/j.jval.2019.03.008. Epub 2019 May 17.
    • Development of Peritoneal Carcinoma in women diagnosed with Serous Tubal Intraepithelial Carcinoma (STIC) following Risk-Reducing Salpingo-Oophorectomy (RRSO).
    • Stanciu PI, Ind TEJ, Barton DPJ, Butler JB, Vroobel KM, Attygalle AD, Nobbenhuis MAE.
    • J Ovarian Res. 2019 May 25;12(1):50. doi: 10.1186/s13048-019-0525-1.
    • Opportunistic Salpingectomy at the Time of Urogynecologic Surgery: Why, in Whom, and How?
    • Catanzarite T, Eskander RN.
    • Female Pelvic Med Reconstr Surg. 2019 May 22. doi: 10.1097/SPV.0000000000000741. [Epub ahead of print]
    • Review
    • Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up.
    • Blok F, Dasgupta S, Dinjens WNM, Roes EM, van Beekhuizen HJ, Ewing-Graham PC.
    • Gynecol Oncol. 2019 May;153(2):326-334. doi: 10.1016/j.ygyno.2019.03.003. Epub 2019 Mar 18.
    • An Alternate Diagnostic Algorithm for the Diagnosis of Intraepithelial Fallopian Tube Lesions.
    • Perrone ME, Reder NP, Agoff SN, Garcia RL, Agnew KJ, Norquist BM, Pennington KP, Swisher EM, Kilgore MR.
    • Int J Gynecol Pathol. 2019 Apr 24. doi: 10.1097/PGP.0000000000000604. [Epub ahead of print]
    • Surgery to Reduce Ovarian Cancer Risk — One Step or Two?
    • Harrison P
    • Medscape. Medscape Oncology. 2019 Mar 25.
    • Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy.
    • Menkiszak J, Chudecka-Głaz A, Cymbaluk-Płoska A, Celewicz A, Kojs Z, Szajda M, Świniarska M, Bedner R, Jurczak A, Celewicz M, Cieszyńska M, Lubiński J, Gronwald J.
    • Hered Cancer Clin Pract. 2019 Mar 14;17:10. doi: 10.1186/s13053-019-0109-5. eCollection 2019.
    • Distinct Histologic, Immunohistochemical and Clinical Features Associated With Serous Endometrial Intraepithelial Carcinoma Involving Polyps.
    • Trinh VQ, Pelletier MP, Echelard P, Warkus T, Sauthier P, Gougeon F, Mès-Masson AM, Provencher DM, Rahimi K.
    • Int J Gynecol Pathol. 2019 Feb 14. doi: 10.1097/PGP.0000000000000591. [Epub ahead of print]
    • Evaluation of screening and risk-reducing surgery for women followed in a high-risk breast/ovarian cancer clinic: it is all about the tubes in BRCA mutation carriers.
    • Stewart ME, Knisely AT, Sullivan MW, Ring KL, Modesitt SC.
    • Gynecol Oncol Rep. 2019 Feb 1;28:18-22. doi: 10.1016/j.gore.2019.01.010. eCollection 2019 May.
    • Population Frequency of Serous Tubal Intraepithelial Carcinoma (STIC) in Clinical Practice Using SEE-Fim Protocol.
    • Samimi G, Trabert B, Geczik AM, Duggan MA, Sherman ME.
    • JNCI Cancer Spectr. 2018 Dec 14;2(4):pky061. doi: 10.1093/jncics/pky061. eCollection 2018 Oct.
    • Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study.
    • Visvanathan K, Shaw P, May BJ, Bahadirli-Talbott A, Kaushiva A, Risch H, Narod S, Wang TL, Parkash V, Vang R, Levine DA, Soslow R, Kurman R, Shih IM.
    • Cancer Prev Res (Phila). 2018 Nov;11(11):697-706. doi: 10.1158/1940-6207.CAPR-18-0009. Epub 2018 Sep 19.
    • Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study.
    • Minig L, Cabrera S, Oliver R, Couso A, Rubio MJ, Iacoponi S, Martin-Salamanca MB, Carballo-Rastrilla S, Cádenas-Rebollo JM, García-Garcia A, Gil-Ibáñez B, Juan-Fita MJ, Patrono MG.
    • Clin Transl Oncol. 2018 Oct;20(10):1337-1344. doi: 10.1007/s12094-018-1865-9. Epub 2018 Apr 5.
    • Risk management adherence following genetic testing for hereditary cancer syndromes: a Singaporean experience.
    • Courtney E, Chin XW, Yuen J, Li ST, Chen Y, Allen JC Jr, Tan V, Lim GH, Ngeow J.
    • Fam Cancer. 2018 Oct;17(4):621-626. doi: 10.1007/s10689-018-0071-9.
    • Surgical prevention strategies in ovarian cancer.
    • Mallen A, Soong TR, Townsend MK, Wenham RM, Crum CP, Tworoger SS.
    • Gynecol Oncol. 2018 Oct;151(1):166-175. doi: 10.1016/j.ygyno.2018.08.005. Epub 2018 Aug 4.
    • Review
    • Change in Inflammatory Biomarkers and Adipose Tissue in BRCA1/2+ Breast Cancer Survivors Following a Yearlong Lifestyle Modification Program.
    • Sturgeon KM, Foo W, Heroux M, Schmitz K.
    • Cancer Prev Res (Phila). 2018 Sep;11(9):545-550. doi: 10.1158/1940-6207.CAPR-18-0098. Epub 2018 Jun 20.
    • Surgery for BRCA, TP53 and PALB2: a literature review.
    • Song CV, Teo SH, Taib NA, Yip CH.
    • Ecancermedicalscience. 2018 Aug 29;12:863. doi: 10.3332/ecancer.2018.863. eCollection 2018.
    • Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
    • Eleje GU, Eke AC, Ezebialu IU, Ikechebelu JI, Ugwu EO, Okonkwo OO.
    • Cochrane Database Syst Rev. 2018 Aug 24;8:CD012464. doi: 10.1002/14651858.CD012464.pub2.
    • Meta-Analysis, Review
    • Outcome and Prognostic Impact of Surgical Staging in Serous Tubal Intraepithelial Carcinoma: A Cohort Study and Systematic Review.
    • Van der Hoeven NMA, Van Wijk K, Bonfrer SE, Beltman JJ, Louwe LA, De Kroon CD, Van Asperen CJ, Gaarenstroom KN.
    • Clin Oncol (R Coll Radiol). 2018 Aug;30(8):463-471. doi: 10.1016/j.clon.2018.03.036. Epub 2018 Apr 22.
    • The risk of stroke after bilateral salpingo-oophorectomy at hysterectomy for benign diseases: A nationwide cohort study.
    • Lai JC, Chou YJ, Huang N, Chen HH, Wang KL, Wang CW, Shen IH, Chang HC.
    • Maturitas. 2018 Aug;114:27-33. doi: 10.1016/j.maturitas.2018.05.007. Epub 2018 May 19.
    • Uptake of risk-reducing surgery in BRCA gene carriers in Wales, UK.
    • Long J, Evans TG, Bailey D, Lewis MH, Gower-Thomas K, Murray A.
    • Breast J. 2018 Jul;24(4):580-585. doi: 10.1111/tbj.12978. Epub 2017 Dec 29.
    • Intra-operative evaluation of prophylactic hysterectomy and salpingo-oophorectomy specimens in hereditary gynaecological cancer syndromes.
    • Wong S, Ratner E, Buza N.
    • Histopathology. 2018 Jul;73(1):109-123. doi: 10.1111/his.13503. Epub 2018 Apr 16.
    • Prophylactic salpingo-oophorectomy & surgical menopause for inherited risks of cancer: the need to identify biomarkers to assess the theoretical risk of premature coronary artery disease.
    • Batulan Z, Maarouf N, Shrivastava V, O'Brien E.
    • Womens Midlife Health. 2018 Apr 27;4:7. doi: 10.1186/s40695-018-0037-y. eCollection 2018.
    • The clinical impact of serous tubal intraepithelial carcinoma on outcomes of patients with high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum.
    • Toptas T, Pestereli E, Simsek T, Bozkurt S, Erdogan G, Karaveli S.
    • J Cancer Res Ther. 2018 Apr-Jun;14(3):587-592. doi: 10.4103/0973-1482.172130.
    • Observations on the origin of ovarian cortical inclusion cysts in women undergoing risk-reducing salpingo-oophorectomy.
    • Park KJ, Patel P, Linkov I, Jotwani A, Kauff N, Pike MC.
    • Histopathology. 2018 Apr;72(5):766-776. doi: 10.1111/his.13444. Epub 2018 Jan 29.
    • Peritoneal carcinomatosis after risk-reducing surgery in BRCA1/2 mutation carriers.
    • Harmsen MG, Piek JMJ, Bulten J, Casey MJ, Rebbeck TR, Mourits MJ, Greene MH, Slangen BFM, van Beurden M, Massuger LFAG, Hoogerbrugge N, de Hullu JA.
    • Cancer. 2018 Mar 1;124(5):952-959. doi: 10.1002/cncr.31211. Epub 2018 Jan 9.


    Who is at risk after risk reduction?

    • Peritoneal cancer arising after total abdominal hysterectomy and bilateral salpingo-oophorectomy for cervical cancer in a patient with right breast cancer and germline mutation of BRCA1 gene: a case report and literature review.
    • Harao M, Ando J, Kamata H, Hoshi N, Igarashi S, Sekiguchi R, Sugano K.
    • Breast Cancer. 2018 Mar;25(2):243-249. doi: 10.1007/s12282-017-0813-9. Epub 2017 Nov 1.
    • Case report, Review
    • Commercially Available Lifestyle Modification Program Decreases Inflammatory Biomarkers in BRCA1/2+ Breast Cancer Survivors.
    • Sturgeon KM, Foo W, Schmitz KH/
    • Cancer Epidemiol Biomarkers Prev. 2018 Mar;27(3):357-357. doi: 10.1158/1055-9965.EPI-18-0063.
    • Conference abstract
    • Synchronous Bilateral Tubal Serous Carcinomas in a Patient With Exon 13 Duplication and Loss of Function of BRCA1.
    • Gurda GT, Serdy KM, Yatsenko SA, Rajkovic A, Carter NJ, Ahmed R, Olawaiye AB, Bhargava R, Elishaev E.
    • Int J Gynecol Pathol. 2018 Mar;37(2):117-122. doi: 10.1097/PGP.0000000000000392.
    • Expression of βV-Tubulin in Secretory Cells of the Fallopian Tube Epithelium Marks Cellular Atypia.
    • Mathew D, Wang Y, Van Arsdale A, Horwitz SB, McDaid H.
    • Int J Gynecol Cancer. 2018 Feb;28(2):363-370. doi: 10.1097/IGC.0000000000001160.
    • Self-compassion, physical fitness and climacteric symptoms in oophorectomized BRCA1/2 mutation carriers.
    • Arts-de Jong M, van Westerop LL, Hoogerbrugge N, Massuger LF, Maas AH, van Beek MH, de Hullu JA.
    • Maturitas. 2018 Feb;108:13-17. doi: 10.1016/j.maturitas.2017.11.002. Epub 2017 Nov 3.
    • [Does ovarian cancer start in the fallopian tubes? Possible implications for preventive adnexal removal].
    • Steenbeek MP, Bulten J, Hoogerbrugge N, Massuger LFAG, Pijnenborg JMA, de Hullu JA.
    • Ned Tijdschr Geneeskd. 2018;162(0):D2337.
    • Case report, [Article in Dutch]
    • Cells of origin of ovarian cancer: ovarian surface epithelium or fallopian tube?
    • Klotz DM, Wimberger P.
    • Arch Gynecol Obstet. 2017 Dec;296(6):1055-1062. doi: 10.1007/s00404-017-4529-z. Epub 2017 Sep 23.
    • Review
    • Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo-Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study.
    • Cortesi L, De Matteis E, Toss A, Marchi I, Medici V, Contu G, Xholli A, Grandi G, Cagnacci A, Federico M.
    • Oncology. [2017 Dec;]93(6):377-386. doi: 10.1159/000479155. Epub 2017 Aug 26.
    • RE: Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
    • Nolan E, Vaillant F, Visvader JE, Lindeman GJ.
    • J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx038.
    • Letter

    Letter, Reply:


    • Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer.
    • Lee YC, Bressel M, Grant P, Russell P, Smith C, Picken S, Camm S, Kiely BE, Milne RL, McLachlan SA, Hickey M, Friedlander ML, Hopper JL, Phillips KA; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).
    • Fam Cancer. 2017 Oct;16(4):461-469. doi: 10.1007/s10689-017-9977-x.
    • Sequential molecular changes and dynamic oxidative stress in high-grade serous ovarian carcinogenesis.
    • Kobayashi H, Ogawa K, Kawahara N, Iwai K, Niiro E, Morioka S, Yamada Y.
    • Free Radic Res. 2017 Oct;51(9-10):755-764. doi: 10.1080/10715762.2017.1383605. Epub 2017 Oct 11.
    • Risk-reducing Salpingo-Oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series.
    • Ricciardi E, Tomao F, Aletti G, Bazzurini L, Bocciolone L, Boveri S, Landoni F, Lapresa MT, Maruccio M, Parma G, Peccatori F, Petrella MC, Zanagnolo V, Colombo N, Maggioni A.
    • Anticancer Res. 2017 Sep;37(9):5241-5248.
    • LEF1 is preferentially expressed in the tubal-peritoneal junctions and is a reliable marker of tubal intraepithelial lesions.
    • Schmoeckel E, Odai-Afotey AA, Schleißheimer M, Rottmann M, Flesken-Nikitin A, Ellenson LH, Kirchner T, Mayr D, Nikitin AY.
    • Mod Pathol. 2017 Sep;30(9):1241-1250. doi: 10.1038/modpathol.2017.53. Epub 2017 Jun 30.
    • The Role of Routine Peritoneal and Omental Biopsies at Risk-Reducing Salpingo-Oophorectomy.
    • Miller H, Pipkin LS, Tung C, Hall TR, Masand RP, Anderson ML.
    • J Minim Invasive Gynecol. 2017 Jul - Aug;24(5):772-776. doi: 10.1016/j.jmig.2017.03.001. Epub 2017 Mar 8.
    • Frequency of "incidental" serous tubal intraepithelial carcinoma (STIC) in women without a history of or genetic risk factor for high-grade serous carcinoma: A six-year study.
    • Meserve EEK, Mirkovic J, Conner JR, Yang E, Muto MG, Horowitz N, Strickland KC, Howitt BE, Crum CP.
    • Gynecol Oncol. 2017 Jul;146(1):69-73. doi: 10.1016/j.ygyno.2017.04.015. Epub 2017 May 4.
    • Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers.
    • Havrilesky LJ, Moss HA, Chino J, Myers ER, Kauff ND.
    • Gynecol Oncol. 2017 Jun;145(3):549-554. doi: 10.1016/j.ygyno.2017.03.025. Epub 2017 Apr 6.
    • Frequency of “incidental” serous tubal intraepithelial carcinoma (STIC) in women without a history of or genetic risk factor for high-grade serous carcinoma: A six-year study.
    • Meserve EEK, Mirkovic J, Conner JR, Yang E, Muto MG, Horowitz N, Strickland KC, Howitt BE, Crum CP.
    • Gynecol Oncol. 2017 May 4. pii: S0090-8258(17)30796-5. doi: 10.1016/j.ygyno.2017.04.015. [Epub ahead of print]
    • Early-onset primary peritoneal carcinoma from atypical cells after risk-reducing salpingo-oophorectomy for BRCA2 mutation carrier: a case report.
    • Shimizu H, Ishikawa T, Iitsuka C, Homma M, Takimoto M, Sekizawa A.
    • Int Cancer Conf J. 2017 Mar 21;6(3):104-108. doi: 10.1007/s13691-017-0287-9. eCollection 2017 Jul.
    • Role of Fallopian Tubes in the Development of Ovarian Cancer.
    • Corzo C, Iniesta MD, Patrono MG, Lu KH, Ramirez PT.
    • J Minim Invasive Gynecol. 2017 Feb;24(2):230-234. doi: 10.1016/j.jmig.2016.12.007. Epub 2016 Dec 19.
    • Review
    • Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers.
    • Lee YJ, Lee SW, Kim KR, Jung KH, Lee JW, Kim YM.
    • J Gynecol Oncol. 2017 Jan;28(1):e3. doi: 10.3802/jgo.2017.28.e3. Epub 2016 Aug 8.
    • Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.
    • Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA, Nathanson KL, Konner JA, Arnold AG, Bogomolniy F, Dao F, Olvera N, Bancroft EK, Goldfrank DJ, Stadler ZK, Robson ME, Brown CL, Leitao MM Jr, Abu-Rustum NR, Aghajanian CA, Blum JL, Neuhausen SL, Garber JE, Daly MB, Isaacs C, Eeles RA, Ganz PA, Barakat RR, Offit K, Domchek SM, Rebbeck TR, Kauff ND.
    • JAMA Oncol. 2016 Nov 1;2(11):1434-1440. doi: 10.1001/jamaoncol.2016.1820.

    Comments on NSGC Discussion Forum Cancer SIG:

    Subject: BRCA1 loss of expression in Uetrine Serous carcinoma

    Subject: Register for August webinar, July webinar slides and recording posted

    Webinar: Cancer SIG Aug Journal Club: Uterine Cancer After RRSO w/o Hysterectomy in Women with BRCA mutations. (NSGC. Cancer SIG Journal Club.)


    Drawing the Line in Risk-Reducing Gynecologic Surgery in Women With a BRCA Mutation.

    Letter, Comment:

    Reservations About Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.

    Letter, Reply:

    Reservations About Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations-Reply.


    BRCA mutations and risk of uterine cancer.

    Press: Uterine cancer risk higher for women with ‘breast cancer gene’ mutation (Washington Post)

    Press: BRCA1 Mutation Increases Uterine Cancer Risk (Medscape/Reuters Health)

    • STIC-ing with what we know.
    • Chen LM.
    • Gynecol Oncol. 2016 Nov;143(2):227-228. doi: 10.1016/j.ygyno.2016.10.007.
    • Editorial
    • Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers.
    • Zakhour M, Danovitch Y, Lester J, Rimel BJ, Walsh CS, Li AJ, Karlan BY, Cass I.
    • Gynecol Oncol. 2016 Nov;143(2):231-235. doi: 10.1016/j.ygyno.2016.08.336. Epub 2016 Sep 9.
    • Incidence and Characteristics of Unsuspected Neoplasia Discovered in High-Risk Women Undergoing Risk Reductive Bilateral Salpingooophorectomy.
    • Poon C, Hyde S, Grant P, Newman M, Ireland Jenkin K.
    • Int J Gynecol Cancer. 2016 Oct;26(8):1415-20. doi: 10.1097/IGC.0000000000000791.
    • Incidental Serous Tubal Intraepithelial Carcinoma and Non-Neoplastic Conditions of the Fallopian Tubes in Grossly Normal Adnexa: A Clinicopathologic Study of 388 Completely Embedded Cases.
    • Seidman JD, Krishnan J, Yemelyanova A, Vang R.
    • Int J Gynecol Pathol. 2016 Sep;35(5):423-429.
    • Primary Peritoneal Carcinoma in a BRCA1/2-negative, PALB2-positive patient.
    • Kahn R, Garcia-Soto A, Silva-Smith R, Pinto A, George SH.
    • Gynecol Oncol Rep. 2016 Aug 2;17:93-5. doi: 10.1016/j.gore.2016.08.001. eCollection 2016.
    • Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies.
    • Hellner K, Miranda F, Fotso Chedom D, Herrero-Gonzalez S, Hayden DM, Tearle R, Artibani M, KaramiNejadRanjbar M, Williams R, Gaitskell K, Elorbany S, Xu R, Laios A, Buiga P, Ahmed K, Dhar S, Zhang RY, Campo L, Myers KA, Lozano M, Ruiz-Miró M, Gatius S, Mota A, Moreno-Bueno G, Matias-Guiu X, Benítez J, Witty L, McVean G, Leedham S, Tomlinson I, Drmanac R, Cazier JB, Klein R, Dunne K, Bast RC Jr, Kennedy SH, Hassan B, Lise S, Garcia MJ, Peters BA, Yau C, Sauka-Spengler T, Ahmed AA.
    • EBioMedicine. 2016 Aug;10:137-49. doi: 10.1016/j.ebiom.2016.06.048. Epub 2016 Jul 2.
    • Primary peritoneal cancer in BRCA carriers after prophylactic bilateral salpingo-oophorectomy.
    • Iavazzo C, Gkegkes ID, Vrachnis N.
    • J Turk Ger Gynecol Assoc. 2016 Jan 12;17(2):73-6. doi: 10.5152/jtgga.2016.15223. eCollection [2016 Jun;].
    • Salpingectomy With Delayed Oophorectomy in BRCA1/2 Mutation Carriers: Estimating Ovarian Cancer Risk.
    • Harmsen MG, IntHout J, Arts-de Jong M, Hoogerbrugge N, Massuger LF, Hermens RP, de Hullu JA.
    • Obstet Gynecol. 2016 Jun;127(6):1054-63. doi: 10.1097/AOG.0000000000001448.
    • Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer.
    • Chay WY, McCluggage WG, Lee CH, Köbel M, Irving J, Millar J, Gilks CB, Tinker AV.
    • Int J Gynecol Cancer. 2016 Mar;26(3):431-6. doi: 10.1097/IGC.0000000000000639.
    • Clinical and Pathological Characteristics of Incidental Diagnostic Early Occult Malignancy After Risk-Reducing Salpingo-Oophorectomy in BRCA Mutation Carriers.
    • Lavie O, Moskoviz MG, Auslender R, Gemer O, Bitterman A, Younes G, Segev Y.
    • Int J Gynecol Cancer. 2016 Feb;26(2):233-9. doi: 10.1097/IGC.0000000000000624.
    • Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): A comprehensive review.
    • Patrono MG, Iniesta MD, Malpica A, Lu KH, Fernandez RO, Salvo G, Ramirez PT.
    • Gynecol Oncol. 2015 Dec;139(3):568-572. doi: 10.1016/j.ygyno.2015.09.018. Epub 2015 Sep 25.
    • Review
    • [Early epithelial lesions in prophylactic annexectomies in patients at high risk of ovarian cancer: Report of a series of 93 cases].
    • Selmes G, Ferron G, Filleron T, Querleu D, Mery E.
    • Gynecol Obstet Fertil. 2015 Oct;43(10):659-64. doi: 10.1016/j.gyobfe.2015.07.006.
    • [Article in French]
    • Cancer SIG Aug Journal Club: Uterine Cancer After RRSO w/o Hysterectomy in Women with BRCA mutations.
    • Melanie Baxter
    • NSGC. Cancer SIG Journal Club. 2016 Aug 25.

    Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.

    • Cancer precursor lesions in the BRCA population at the time of prophylactic salpingo-oophorectomy: Accuracy of assessment and potential surrogate marker for prevention.
    • Lheureux S, Shaw PA, Karakasis K, Oza AM.
    • Gynecol Oncol. 2015 Aug;138(2):235-237. doi: 10.1016/j.ygyno.2015.06.014. Epub 2015 Jun 10.
    • Editorial / Commentary
    • Opportunistic salpingectomies for the prevention of a high-grade serous carcinoma: a statement by the Kommission Ovar of the AGO.
    • Pölcher M, Hauptmann S, Fotopoulou C, Schmalfeldt B, Meinhold-Heerlein I, Mustea A, Runnebaum I, Sehouli J.
    • Arch Gynecol Obstet. 2015 Jul;292(1):231-4. doi: 10.1007/s00404-015-3697-y. Epub 2015 Apr 26.
    • Review
    • Low grade serious carcinoma of the peritoneum in a BRCA1 carrier previously diagnosed with a "low-grade serous tubal intra-epithelial carcinoma" (STIC) on risk reducing surgery.
    • Chay WY, Horlings HM, Tinker AV, Gelmon KA, Gilks CB.
    • Gynecol Oncol Rep. 2015 Mar 28;12:72-4. doi: 10.1016/j.gore.2015.03.007. eCollection 2015.
    • Serous Tubal Intraepithelial Carcinoma Localizes to the Tubal-peritoneal Junction: A Pivotal Clue to the Site of Origin of Extrauterine High-grade Serous Carcinoma (Ovarian Cancer).
    • Seidman JD.
    • Int J Gynecol Pathol. 2015 Mar;34(2):112-20. doi: 10.1097/PGP.0000000000000123.
    • Stopping ovarian cancer screening in BRCA1/2 mutation carriers: Effects on risk management decisions & outcome of risk-reducing salpingo-oophorectomy specimens.
    • van Driel CM, de Bock GH, Arts HJ, Sie AS, Hollema H, Oosterwijk JC, Mourits MJ.
    • Maturitas. 2015 Mar;80(3):318-22. doi: 10.1016/j.maturitas.2014.12.009. Epub 2014 Dec 30.
    • Endometrial adenocarcinoma after risk reducing bilateral salpingo-oophorectomy
    • Catherine Naber, Elise Everett, Cheung Wong
    • Gynecologic Oncology, 2015 Feb;136(2):395. 2014 NEAGO Abstracts. doi: 10.1016/j.ygyno.2014.11.024.
    • Conference abstract
    • Ovarian cancer risk after salpingectomy: a nationwide population-based study.
    • Falconer H, Yin L, Grönberg H, Altman D.
    • J Natl Cancer Inst. 2015 Jan 27 [2015 Feb;];107(2). pii: dju410. doi: 10.1093/jnci/dju410. Print 2015 Feb.

    Comment / Editorial

    Salpingectomy as a potential ovarian cancer risk-reducing procedure.

    Research snippets.


    • Salpingectomy as a potential ovarian cancer risk-reducing procedure.
    • Poole EM, Rice MS, Crum CP, Tworoger SS.
    • J Natl Cancer Inst. 2015 Jan 27 [2015 Feb;];107(2). pii: dju490. doi: 10.1093/jnci/dju490. Print 2015 Feb.

    Ovarian cancer risk after salpingectomy: a nationwide population-based study.

    • Serous tubal intraepithelial carcinoma: an incidental finding at the time of prophylactic bilateral salpingo-oophorectomy.
    • Vaughan MH, Modesitt SC, Mo Y, Trowbridge ER.
    • Case Rep Obstet Gynecol. 2015;2015:760429. doi: 10.1155/2015/760429. Epub 2015 Feb 23.
    • Occult and subsequent gynecologic cancers following risk-reducing salpingo-oophorectomies (RRSO) in BRCA mutation carriers.
    • Zakhour M, Karlan BY, Walts AE, Gross J, Rimel BJ, Walsh C, Li AJ, Cass I.
    • Gynecologic Oncology. 2014 Nov;135(2):384. 2014 WAGO ABSTRACTS. doi: 10.1016/j.ygyno.2014.07.013.
    • Conference abstract
    • A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers.
    • Cass I, Walts AE, Barbuto D, Lester J, Karlan B.
    • Gynecol Oncol. 2014 Sep;134(3):492-7. doi: 10.1016/j.ygyno.2014.07.084. Epub 2014 Jul 12.
    • Genomic Aberrations of BRCA1-Mutated Fallopian Tube Carcinomas.
    • Hunter SM, Ryland GL, Moss P; kConFab Investigators, Gorringe KL, Campbell IG.
    • Am J Pathol. 2014 Jun;184(6):1871-6. doi: 10.1016/j.ajpath.2014.02.013. Epub 2014 Apr 13.
    • Serous tubal intraepithelial carcinoma in a Japanese woman with a deleterious BRCA1 mutation.
    • Ishikawa H, Kiyokawa T, Utsuno E, Matsushita K, Nomura F, Shozu M.
    • Jpn J Clin Oncol. 2014 Jun;44(6):597-601. doi: 10.1093/jjco/hyu035. Epub 2014 Apr 9.
    • Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation.
    • Finch AP, Lubinski J, Møller P, Singer CF, Karlan B, Senter L, Rosen B, Maehle L, Ghadirian P, Cybulski C, Huzarski T, Eisen A, Foulkes WD, Kim-Sing C, Ainsworth P, Tung N, Lynch HT, Neuhausen S, Metcalfe KA, Thompson I, Murphy J, Sun P, Narod SA.
    • J Clin Oncol. 2014 May 20;32(15):1547-53. doi: 10.1200/JCO.2013.53.2820. Epub 2014 Feb 24.

    Comment, Editorial:

    A major step forward for BRCA1/2-related cancer risk management.

    Research news: Oophorectomy in women with BRCA1 or BRCA2 mutations. (Lancet Oncology)

    Press: Early Surgery in BRCA1 Carriers Lowers Ovarian Cancer Risk. (Medscape)

    Press: Young women with BRCA1 mutation 'should remove ovaries earlier'. (Medical News Today)

    • Occult tubal carcinoma found at risk reducing salpingectomy in a BRCA1 carrier.
    • Kim SH, Frey MK, Blank SV.
    • Gynecol Oncol Case Rep. 2014 Apr 2;9:1-2. doi: 10.1016/j.gynor.2014.03.003. eCollection 2014.
    • Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations.
    • Conner JR, Meserve E, Pizer E, Garber J, Roh M, Urban N, Drescher C, Quade BJ, Muto M, Howitt BE, Pearlman MD, Berkowitz RS, Horowitz N, Crum CP, Feltmate C.
    • Gynecol Oncol. 2014 Feb;132(2):280-6. doi: 10.1016/j.ygyno.2013.12.009. Epub 2013 Dec 12.


    Risk reducing salpingo-oophorectomy for BRCA mutation carriers: twenty years later.

    • Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral.
    • Ingham SL, Sperrin M, Baildam A, Ross GL, Clayton R, Lalloo F, Buchan I, Howell A, Evans DG.
    • Breast Cancer Res Treat. 2013 Dec;142(3):611-8. doi: 10.1007/s10549-013-2765-x. Epub 2013 Nov 20.
    • Tubal ligation, hysterectomy and epithelial ovarian cancer in the New England Case-Control Study.
    • Rice MS, Murphy MA, Vitonis AF, Cramer DW, Titus LJ, Tworoger SS, Terry KL.
    • Int J Cancer. 2013 Nov 15;133(10):2415-21. doi: 10.1002/ijc.28249. Epub 2013 Jul 9.
    • Clinical Outcome of Isolated Serous Tubal Intraepithelial Carcinomas (STIC).
    • Wethington SL, Park KJ, Soslow RA, Kauff ND, Brown CL, Dao F, Otegbeye E, Sonoda Y, Abu-Rustum NR, Barakat RR, Levine DA, Gardner GJ.
    • Int J Gynecol Cancer. 2013 Nov;23(9):1603-11. doi: 10.1097/IGC.0b013e3182a80ac8.
    • Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis.
    • Bijron JG, Seldenrijk CA, Zweemer RP, Lange JG, Verheijen RH, van Diest PJ.
    • Am J Surg Pathol. 2013 Aug;37(8):1123-30. doi: 10.1097/PAS.0b013e318282da7f.
    • Case report

    Letter, Comment:

    Fallopian tube intraluminal tumor spread.

    Letter, Comment:

    Serous carcinogenesis: a classic causality dilemma or which came first... ?

    • Do deeper sections increase the frequency of detection of serous tubal intraepithelial carcinoma (STIC) in the "sectioning and extensively examining the FIMbriated end" (SEE-FIM) protocol?
    • Mahe E, Tang S, Deb P, Sur M, Lytwyn A, Daya D.
    • Int J Gynecol Pathol. 2013 Jul;32(4):353-7. doi: 10.1097/PGP.0b013e318264ae09.
    • Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions.
    • Chene G, Tchirkov A, Pierre-Eymard E, Dauplat J, Raoelfils I, Cayre A, Watkin E, Vago P, Penault-Llorca F.
    • Clin Cancer Res. 2013 Jun 1;19(11):2873-82. doi: 10.1158/1078-0432.CCR-12-3947. Epub 2013 Apr 15.

    Letter, Comment:

    Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions--letter.

    Letter, Reply:

    Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions--response.

    • Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy.
    • Powell CB, Swisher EM, Cass I, McLennan J, Norquist B, Garcia RL, Lester J, Karlan BY, Chen L.
    • Gynecol Oncol. 2013 May;129(2):364-71. doi: 10.1016/j.ygyno.2013.01.029. Epub 2013 Feb 4.
    • Salpingectomy: Can removing the fallopian tubes lower ovarian cancer risk?
    • Ilana Cass, Doug Levine
    • FORCE. Be Empowered Webinars. 2013 Apr 11.
    • Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers.
    • Reitsma W, Mourits MJ, de Bock GH, Hollema H.
    • Mod Pathol. 2013 Apr;26(4):572-8. doi: 10.1038/modpathol.2012.169. Epub 2012 Oct 19.
    • Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.
    • Reitsma W, de Bock GH, Oosterwijk JC, Bart J, Hollema H, Mourits MJ.
    • Eur J Cancer. 2013 Jan;49(1):132-41. doi: 10.1016/j.ejca.2012.07.021. Epub 2012 Aug 21.
    • Pre-diagnosis oophorectomy, estrogen therapy and mortality in a cohort of women diagnosed with breast cancer.
    • Nichols HB, Trentham-Dietz A, Newcomb PA, Egan KM, Titus LJ, Hampton JM, Visvanathan K.
    • Breast Cancer Res. 2013;15(5):R99.
    • Tubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controls.
    • Mingels MJ, Roelofsen T, van der Laak JA, de Hullu JA, van Ham MA, Massuger LF, Bulten J, Bol M.
    • Gynecol Oncol. 2012 Oct;127(1):88-93. doi: 10.1016/j.ygyno.2012.06.015. Epub 2012 Jun 16.
    • Peritoneal cytology in risk-reducing salpingo-oophorectomy: Implications for cancer outcomes.
    • Chen L, McAlhaney S, Fehniger J, Powell C, Crawford B, Mak J, Rabban J.
    • Gynecol Oncol. 2012 Oct;127(1 Suppl):S17. doi: 10.1016/j.ygyno.2012.07.047.
    • Conference abstract
    • A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers.
    • Sigal BM, Munoz DF, Kurian AW, Plevritis SK.
    • Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1066-77. doi: 10.1158/1055-9965.EPI-12-0149. Epub 2012 May 3.
    • Effectiveness of risk-reducing salpingo-oophorectomy in preventing ovarian cancer in a high-risk French Canadian population.
    • Bacha OM, Gregoire J, Grondin K, Edelweiss MI, Laframboise R, Simard J, Plante M.
    • Int J Gynecol Cancer. 2012 Jul;22(6):974-8. doi: 10.1097/IGC.0b013e318257b936.
    • Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers.
    • Finkelman BS, Rubinstein WS, Friedman S, Friebel TM, Dubitsky S, Schonberger NS, Shoretz R, Singer CF, Blum JL, Tung N, Olopade OI, Weitzel JN, Lynch HT, Snyder C, Garber JE, Schildkraut J, Daly MB, Isaacs C, Pichert G, Neuhausen SL, Couch FJ, van't Veer L, Eeles R, Bancroft E, Evans DG, Ganz PA, Tomlinson GE, Narod SA, Matloff E, Domchek S, Rebbeck TR.
    • J Clin Oncol. 2012 Apr 20;30(12):1321-8. doi: 10.1200/JCO.2011.37.8133. Epub 2012 Mar 19.
    • Online tool to guide decisions for BRCA1/2 mutation carriers.
    • Kurian AW, Munoz DF, Rust P, Schackmann EA, Smith M, Clarke L, Mills MA, Plevritis SK.
    • J Clin Oncol. 2012 Feb 10;30(5):497-506. doi: 10.1200/JCO.2011.38.6060. Epub 2012 Jan 9.

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: An Online BRCA Positive Decision Guidance Tool.


    Are we ready for online tools in decision making for BRCA1/2 mutation carriers?

    Press: Are We Ready for Online Tools in Decision Making for BRCA1/2 Mutation Carriers? (Journal of Clinical Oncology)

    Press: Online tool helps those with BRCA mutations understand options. (Medical Xpress)

    • Physician data query (PDQ®) update.
    • [No authors listed]
    • J Natl Cancer Inst. 2012 Feb 8;104(3):176. doi: 10.1093/jnci/djs025. Epub 2012 Jan 23.